MaxCyte Inc at Cowen Health Care Conference Transcript
Well, good to see everybody. Thanks for coming. 43rd Annual TD Cowen Health Care Conference. And I'm Max Masucci, life science and diagnostic tools analyst here at TD Cowen. And we're very pleased to be joined by MaxCyte, market-leading non-viral cell engineering company and a critical enabler, in our opinion, of the cell therapy field.
And so next to me is the company's President and CEO, Doug Doerfler. So Doug, great to see you in person.
Thanks, Max. You, too.
So I'm not sure what the mix is in the crowd of those that are new to the MaxCyte story and those that are familiar. So why don't we start with a brief, if possible, overview of MaxCyte's business today compared to when you founded the company in 1998? And then just any key differentiating factors of your ExPERT non-viral cell engineering platform technologies.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |